First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis

BACKGROUND: A first-line biologic treatment for metastatic colorectal cancer (mCRC) is still controversial. We, therefore, performed a meta-analysis to determine the efficacy of first-line cetuximab versus bevacizumab for RAS and BRAF wild-type mCRC. METHODS: In March 2018, an electronic search of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Bobo, Wang, Xin, Wei, Mingtian, Wang, Quan, Li, Jiang, Bi, Liang, Deng, Xiangbing, Wang, Ziqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437996/
https://www.ncbi.nlm.nih.gov/pubmed/30922269
http://dx.doi.org/10.1186/s12885-019-5481-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437996/
https://www.ncbi.nlm.nih.gov/pubmed/30922269
http://dx.doi.org/10.1186/s12885-019-5481-z

Ejemplares similares